Immediate Impact
5 from Science/Nature 53 standout
Citing Papers
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
2023 Standout
Lung cancer screening
2022 Standout
Works of Glen Goss being referenced
Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort
2019
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.
2010
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Glen Goss | 287 | 168 | 137 | 19 | 406 | |
| Jackie Hodgetts | 318 | 113 | 133 | 15 | 435 | |
| Matthew Perry | 287 | 134 | 64 | 13 | 449 | |
| Naoya Horichi | 249 | 169 | 155 | 23 | 422 | |
| B. Melosky | 206 | 137 | 68 | 22 | 424 | |
| Van Echo Da | 288 | 136 | 115 | 18 | 391 | |
| J.-F. Cordier | 97 | 227 | 128 | 23 | 430 | |
| Macdonald Js | 247 | 119 | 80 | 20 | 434 | |
| S. Caldiera | 167 | 142 | 90 | 22 | 458 | |
| Diana Almader‐Douglas | 169 | 87 | 57 | 30 | 417 | |
| Xiuling Zhou | 232 | 122 | 70 | 14 | 356 |
All Works
Loading papers...